Scribe Therapeutics Inc. (SCTX)
Nasdaq: SCTX · Biological Products, (No Diagnostic Substances) · filing with the SEC since 2021
Who owns Scribe Therapeutics Inc.
As filed with the SECHolders of 5% or more
4
Aghazadeh Behzad holds 16.4% of Common Stock, $0.001 par value per share, as its SCHEDULE 13D filed Jul 30, 2026 says.
Directors and officers
11
report now, of 11 people on the record since 2026. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 4 named at left.
Holders of 5% or moreshare of the class, as filed
Aghazadeh Behzad
SCHEDULE 13D · filed Jul 30, 2026 · Common Stock, $0.001 par value per share
RA Capital Management, L.P.
SCHEDULE 13G · filed Aug 3, 2026 · Common Stock, $0.001 par value per share
Eli Lilly & Co.
SCHEDULE 13D · filed Jul 30, 2026 · Common stock, $0.001 par value per share
Orbimed Advisors LLC
SCHEDULE 13D · filed Jul 29, 2026 · Common Stock
What SCTX reports owning in othersstakes of 5% or more, and other ties
Scribe Therapeutics Inc. reports no stake in another company in the record.
Insider tradesForm 4
0sales
8purchases
0sales on a scheduled plan
0people selling
$0sold, in dollars
$66.3Mbought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window6 of 20 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Avoro Ventures LLC | director | 0 | $0 | 0 | 3 | $36.3M |
| Parrot David | Chief Financial Officer | 0 | $0 | 0 | 2 | $0 |
| Lucas Svetlana | Chief Business Officer | 0 | $0 | 0 | 1 | $0 |
| Gordon Carl L | director | 0 | $0 | 0 | 1 | $15.0M |
| Orbimed Advisors LLC | director | 0 | $0 | 0 | 1 | $15.0M |
| Ah Equity Partners Bio II, L.L.C. | 10% owner | 0 | $0 | 0 | 1 | $5.0M |